Oncolytic viruses and checkpoint inhibitors: combination therapy in clinical trials

Advances in the understanding of cancer immunotherapy and the development of multiple checkpoint inhibitors have dramatically changed the current landscape of cancer treatment. Recent large-scale phase III trials (e.g. PHOCUS, OPTiM) are establishing use of oncolytic viruses as another tool in the c...

Descripción completa

Detalles Bibliográficos
Autores principales: LaRocca, Christopher J., Warner, Susanne G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6234197/
https://www.ncbi.nlm.nih.gov/pubmed/30426287
http://dx.doi.org/10.1186/s40169-018-0214-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6234197/
https://www.ncbi.nlm.nih.gov/pubmed/30426287
http://dx.doi.org/10.1186/s40169-018-0214-5

Ejemplares similares